Contact:
Mento A."Chuck" Soponis
Chief Executive Officer
Oragenics, Inc.
(386) 418-4018
                                                           FOR IMMEDIATE RELEASE

            ORAGENICS RECEIVES $2.4 MILLION THROUGH WARRANT EXERCISE

                    COMPANY RETAINS INVESTOR RELATIONS FIRM.

ALACHUA FL (JANUARY 5, 2004) - Oragenics, Inc. (TSX-V: ORA.U) announced today
that all warrant holders exercised their Series A warrants which were to expire
December 24, 2003. Exercise of the 1,200,000 Series A warrants at the $2.00
exercise price resulted in a total of $2.4 million (U.S.) received by the
Company.

The Company also announced that it had retained MontRidge LLC to serve as its
investor relations consultant beginning in January of 2004. Since 1991 MontRidge
has worked closely with biotechnology industry clients to achieve their
financing goals. MontRidge is located in Ridgefield, Connecticut.


Oragenics, Inc. is an emerging biotechnology research and development company
that began operations in 1999. Located in Alachua, Florida at the University of
Florida's Sid Martin Biotechnology Development Incubator, Oragenics is
developing three new healthcare products. The most advanced product is an oral
rinse for the prevention of tooth decay, which is anticipated to enter clinical
trials in 2004. The second product in pre-clinical development is a
broad-spectrum antibiotic. Oragenics is also developing a probiotic product to
maintain oral health. For more information about Oragenics, please consult the
Company's website at www.oragenics.com.

                                   # # # # # #

The TSX Venture Exchange has not reviewed and does not accept responsibility for
                 the adequacy or accuracy of this news release.